• Boc-D-FMK: From Apoptosis Control to Translation

  2026-08-26

  A mechanistic and strategic guide to using Boc-D-FMK as a pan-caspase inhibitor in apoptosis research, inflammation research, renal endothelial inflammation models, and hepatocyte apoptosis models, with a framework for translating pathway-level observations into stronger disease hypotheses.

• PGF2α/PTGFR Controls Endometrial Breakdown

  2026-08-25

  A 2024 mouse menstrual-like model study identifies PGF2α signaling through PTGFR as a regulator of endometrial shedding and vascular remodeling downstream of progesterone withdrawal. Pharmacological inhibition, molecular profiling, histology, and chromatin assays connect PTGFR activity with HIF-1α, VEGF-A, angiostatin, and vascular permeability, offering a mechanistic framework for studying menstrual-like tissue breakdown.

• LRPPRC–Dasatinib Dual-Genome OXPHOS Synergy

  2026-08-25

  The reference study identifies Dasatinib as a synergistic partner for LRPPRC inhibition and explains the effect through complementary disruption of nuclear- and mitochondrial genome-encoded OXPHOS programs. Its screening and validation strategy provides a framework for studying metabolism-directed combination therapy while highlighting the need for careful mechanistic and translational validation.

• AT-406 (SM-406): Applied Apoptosis Workflows

  2026-08-24

  AT-406 (SM-406) links multi-IAP antagonism to practical apoptosis assays, combination studies, and translational oncology models. This workflow-focused guide covers dosing, mechanistic readouts, carboplatin sensitization, xenograft context, and troubleshooting for reproducible cancer research.

• Bone Transport Links TGF-β1 to Diabetic Foot Repair

  2026-08-23

  This rat study identifies TGF-β1/TGFBR1 activation as a mechanistic bridge between bone transport, angiogenesis, immune regulation, and diabetic foot ulcer repair. Its combined surgical, proteomic, molecular, and histological design supports pathway involvement while also highlighting the need for better-defined inhibitors and clinical validation.

• HotStart 2X Green qPCR Master Mix for COPD

  2026-08-22

  Build sensitive, reproducible SYBR Green assays for PM2.5-related inflammation, oxidative stress, and airway remodeling research. This workflow shows how hot-start specificity, melt-curve control, and disciplined normalization can support real-time PCR gene expression analysis and RNA-seq validation.

• Pregnenolone Carbonitrile: From CYP3A to Water Balance

  2026-08-21

  Pregnenolone Carbonitrile is more than a conventional rodent PXR agonist for xenobiotic metabolism research. By combining hepatic CYP3A induction, antifibrotic activity, and newly described hypothalamic AVP regulation, this article outlines a translational framework for designing more informative PXR experiments.

• Clodronate Liposomes for Liver I/R Studies

  2026-08-21

  Clodronate Liposomes provide a practical loss-of-function tool for testing whether macrophages drive tissue injury or therapeutic response in vivo. This workflow translates a hepatic ischemia-reperfusion study into controlled depletion, matched liposome controls, and cell-state-aware readouts rather than relying on serum biomarkers alone.

• Valemetostat BA4816: Reliable EZH2 Assay Design

  2026-08-20

  This scenario-driven guide shows how Valemetostat (SKU BA4816) can be integrated into reproducible viability, proliferation, and cytotoxicity workflows. It connects biochemical potency, formulation choices, exposure design, data interpretation, and vendor selection without treating cellular responses as direct substitutes for target-level measurements.

• Everolimus (RAD001): mTOR Research Guide

  2026-08-20

  Everolimus, also called RAD001, is an orally bioavailable mTOR pathway inhibitor that forms an FKBP12 complex and suppresses downstream signaling. Its reported in vitro activity in Panc-1 and small cell lung cancer cells should be interpreted separately from clinically relevant serum exposure and from direct cell-death measurements.

• Erlotinib Workflows for EGFR Cancer Research

  2026-08-19

  Erlotinib, also called NSC 718781, provides a rapid pharmacologic way to interrogate EGFR activation, proliferation, and apoptosis in cancer models. This guide connects quantitative EGFR assays with the reference study’s SCUBE3 findings, helping researchers distinguish direct receptor blockade from broader changes in tumor-cell survival and immune signaling.

• LY2228820: A Smarter p38 MAPK Assay Strategy

  2026-08-19

  LY2228820 is a selective p38 MAP kinase inhibitor for dissecting inflammatory, stress, and tumor-associated signaling. This article develops a mechanism-aware assay strategy that distinguishes direct kinase blockade from changes in p38 dephosphorylation and downstream phenotype.

• Tacrolimus (FK506) Workflow & Troubleshooting

  2026-08-18

  Build more reproducible T-cell, cytokine, transplantation, and autoimmune assays with Tacrolimus (FK506), a potent FKBP12–calcineurin pathway inhibitor. This guide connects practical dosing and formulation choices with genetic controls, comparative immunophilin biology, and troubleshooting strategies.

• Leptin (116-130), amide, mouse: Assay Guide

  2026-08-17

  A scenario-based guide to using Leptin (116-130), amide, mouse (SKU A1024) in cell viability, proliferation, and cytotoxicity workflows. It covers peptide handling, assay compatibility, dose-response design, data interpretation, and evidence-based vendor selection.

• V5 Epitope Tag Peptide: Mechanism and Use

  2026-08-17

  The V5 Epitope Tag Peptide is a synthetic 14-amino-acid GKPIPNPLLGLDST peptide for antibody-mediated detection of recombinant proteins. Its high reported purity, solvent-specific solubility, and compatibility with Western blotting, immunoprecipitation, and imaging support controlled protein-tagging workflows.

455 records 7/31 page Previous Next First page 上5页 678910 下5页 Last page